Screener
Arcus Biosciences RCUS Business Segments — Partnership reimbursements
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept rcus:PartnershipReimbursements.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Late-stage development programs (1) | 51 | 74 | 111 | 129 |
| Early-stage development and preclinical programs (2) | 21 | 38 | 39 | 80 |
| Compensation and personnel costs | 58 | 61 | 129 | 128 |
| Depreciation and amortization | 2 | 2 | 5 | 5 |
| Interest income, net | (5) | (8) | (11) | (18) |
| Other segment items (3) | 22 | 26 | 40 | 47 |
| Partnership reimbursements | (17) | (33) | (36) | (71) |
| Segment net income (loss) and Consolidated net income (loss) | $(91) | — | $(219) | $(112) |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's business segments — partnership reimbursements?
- Arcus Biosciences (RCUS) reported business segments — partnership reimbursements of -$17M in Q2 2026.
- How has Arcus Biosciences's business segments — partnership reimbursements changed year-over-year?
- Arcus Biosciences's business segments — partnership reimbursements increased by 48.5% year-over-year, from -$33M to -$17M.
- What is the long-term trend for Arcus Biosciences's business segments — partnership reimbursements?
- Over 3 years (2022 to 2025), Arcus Biosciences's business segments — partnership reimbursements has grown at a -7.8% compound annual growth rate (CAGR), from -$162M to -$127M.
- What does business segments — partnership reimbursements mean?
- Represents the portion of development costs recovered from strategic partners or collaborators under shared-risk agreements. This metric is a critical indicator of the company's ability to leverage external funding to offset the high costs of clinical development.
Ask your AI about Arcus Biosciences's business segments — partnership reimbursements.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude